DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc (NASDAQ:HZNP) announced the early completion of enrollment for the confirmatory Phase 3 trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED). The study (NCT03298867 and EudraCT 2017-002763-18) enrolled 83 patients at 13 sites across the United States, Germany and Italy. Topline results are expected in the second quarter of 2019. “Our success in rapidly enrolling this trial speaks to the significant unmet ne
Category: Business
Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences has boosted its finance team with two key appointments, Chief Financial Officer Julie Feder and VP of Finance Kylie Reynolds.
BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has closed the previously announced transaction with Juvenescence Limited, a global l…
PolyActiva Commences Its First Phase I Clinical Trial with Potential to Improve Daily Lives of Millions of Glaucoma Patients
MELBOURNE, Australia–(BUSINESS WIRE)–Revolutionary new glaucoma treatment, which could remove need for eye drop use, enters clinical trials with USD$12m venture capital-backing.
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced t…
Global Optical Coherence Tomography for Ophthalmology Market 2018-2022| Conventional OCT Systems Dominates the Global Market| Technavio
LONDON–(BUSINESS WIRE)–#MedicalImaging–Technavio market research analysts expect the global optical coherence tomography for ophthalmology market to grow at a CAGR of almost 7% until 2022.
Patient-Driven Gene Therapy Company ReflectionBio Receives Orphan Drug Designation From U.S. FDA For the Treatment of Bietti’s Crystalline Dystrophy (BCD)
HONG KONG & NEW YORK–(BUSINESS WIRE)–Reflection Biotechnologies Limited (“ReflectionBio”), a gene therapy company committed to the research and development of life-changing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ReflectionBio’s RBIO-101 program (AAV.CYP4V2), an AAV-based gene therapy product for treating Bietti’s Crystalline Dystrophy (BCD). “Receiving orphan drug designation from the FDA is a miles
$3 Billion Retinal Surgery Devices Market – Global Forecast to 2025 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinal Surgery Devices Market (By Devices Segment, Application, Geography, Region and Company Profile) – Global Forecast to 2025” company profile has been added to ResearchAndMarkets.com’s offering. The global retinal sur…
EyeSouth Expands into South Florida Through Affiliation with Florida Eye Microsurgical Institute
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed a strategic partnership with Florida Eye Microsurgical Institute and Boynton Beach ASC (“Florida Eye Microsurgical”), expanding its presence into the South Florida region. EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a leading lower middle market healthcare private equity firm. Florida Eye Microsurgical is led by ophthalmolog
The $3.91Bn Global Market for Eye Testing Equipment to 2025: Analysis by Device, Application, End-User and Region – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Eye Testing Equipment Market by Device, Application, and End User – Global Opportunity Analysis and Industry Forecast, 2017-2025” report has been added to ResearchAndMarkets.com’s offering. The global eye testing equipment…
Glaukos Announces Participation in Wells Fargo Healthcare Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published in Proceedings of the National Academy of Sciences
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that Penn and University of Florida scientists published proof-of-concept study results on an AAV gene therapy product candidate.
Global Contact Lens Solutions Market 2018-2022| Americas Dominates the Global Market| Technavio
LONDON–(BUSINESS WIRE)–#HealthandWellness–Technavio forecast the global contact lens solutions market to accelerate at a CAGR of around 2% during 2018-2022.
EyeQue Amplía la Supervisión de la Visión para Consumidores, al Agregar Pruebas de Sensibilidad de Color y Contraste al Detector de la Visión Interna
NEWARK, California–(BUSINESS WIRE)–EyeQue®, el líder galardonado en dispositivos de salud para la visión a precios accesibles en el hogar, anunció hoy la adición de dos nuevas pruebas de visión a su detector de la visión EyeQue Insight™, prueba de sensibilidad de color y contraste de la visión. EyeQue Insight combina un visor binocular, una aplicación móvil y un servicio basado en la nube para crear el primer detector de visión controlado por teléfono inteligente del mundo. Desde su disponibi
MC2 Therapeutics maakt positieve resultaten bekend van Fase 3 klinisch onderzoek dat MC2-01 Cream vergelijkt met Taclonex® bij volwassenen met psoriasis
KOPENHAGEN, Denemarken–(BUSINESS WIRE)–MC2 Therapeutics A/S, een opkomend farmaceutisch bedrijf dat de volgende generatie patiëntvriendelijke lokale therapieën voor huid- en oogziekten ontwikkelt, heeft vandaag de volgende goede gegevens van haar Amerikaanse Fase 3-studie (n = 796) over het onderzoeksmedicijn MC2-01 Cream (calcipotrieen en betamethasondipropionaat, w/w 0,005%/0,064%) van het bedrijf aangekondigd: Primaire eindpunt MC2-01 Cream is beter dan Taclonex® Topical Suspension (‘Taclo
MC2 Therapeutics meldet positive Topline-Ergebnisse aus der klinischen Phase-3-Studie zum Vergleich von MC2-01-Creme und Taclonex® bei erwachsenen Patienten mit Psoriasis
KOPENHAGEN, Dänemark–(BUSINESS WIRE)–MC2 Therapeutics A/S, ein aufstrebendes Pharmaunternehmen, das patientenfreundliche topische Therapeutika der nächsten Generation für Haut- und Augenkrankheiten entwickelt, gab heute die folgenden Topline-Daten aus seiner US-amerikanischen Phase-3-Studie (n=796) zu dem Prüfpräparat des Unternehmens, MC2-01-Creme (Calcipotriol und Betamethason-Dipropionat, w/w 0,005 %/0,064 %), bekannt: Primärer Endpunkt MC2-01-Creme ist Taclonex® Topical Suspension („Taclo
MC2 Therapeutics anuncia resultados positivos de primera línea del ensayo clínico de fase 3 que compara la crema MC2-01 con Taclonex ® en adultos con psoriasis
COPENHAGUE, Dinamarca–(BUSINESS WIRE)–MC2 Therapeutics A/S, una empresa farmacéutica emergente que desarrolla terapias tópicas de próxima generación cómodas para el paciente para enfermedades cutáneas y oculares, ha anunciado los siguientes datos de primera línea de su estudio de fase 3 en Estados Unidos (n=796) de su fármaco en fase de investigación, la crema MC2-01 (calcipotrieno y dipropionato betametasona, al 0,005%/0,064%): Principal criterio de evaluación La crema MC2-01 es superior a l
EyeQue Expands Vision Monitoring for Consumers, Adding Color and Contrast Sensitivity Tests to Insight Vision Screener
NEWARK, Calif.–(BUSINESS WIRE)–#seebeyond–EyeQue brings affordable at-home vision care to people everywhere, adding two new tests to the Insight – color & contrast sensitivity tests
MC2 Therapeutics annuncia risultati top-line positivi della sperimentazione clinica di fase 3 di raffronto tra la crema MC2-01 e Taclonex® negli adulti con psoriasi
COPENAGHEN, Danimarca–(BUSINESS WIRE)–MC2 Therapeutics A/S, casa farmaceutica emergente dedita allo sviluppo di terapie topiche di nuova generazione pratiche da usare per le affezioni della cute e degli occhi, ha annunciato in data odierna i seguenti dati top-line della sperimentazione di fase 3 condotta negli USA (n=796) del farmaco in sperimentazione dell’azienda, la crema MC2-01 (calcipotriolo e betametasone dipropionato, m/m 0,005%/0,064%). Endpoint primario La crema MC2-01 è superiore a
MC2 Therapeutics Announces Positive Top-line Results from Phase 3 Clinical Trial Comparing MC2-01 Cream to Taclonex® in Adults with Psoriasis
COPENHAGEN, Denmark–(BUSINESS WIRE)–MC2 Therapeutics A/S, an emerging pharmaceutical company developing next generation patient-friendly topical therapies for skin and eye diseases, today announced the following top-line data from its US Phase 3 study (n=796) on the company’s investigational drug, MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%): Primary end-point MC2-01 Cream is superior to Taclonex® Topical Suspension (“Taclonex®”) at Week 8 based on treatment